title: Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.
abstract: The activity of ceftolozane/tazobactam was tested against 50 nonduplicate Pseudomonas aeruginosa from 18 cystic fibrosis children collected in 2012-2014. These isolates were multidrug resistant with susceptibility to meropenem, ceftazidime, and piperacillin/tazobactam of 46%, 58%, and 50%, respectively. Ceftolozane/tazobactam was the most active with MIC50, MIC90, and percent susceptibility of 2mg/L, 8 mg/L, and 86%.
authors.affiliation: Center for Anti-Infective Research & Development, Hartford Hospital, Hartford, CT, USA. Electronic address: joseph.kuti@hhchealth.org.
authors.forename: Joseph L
authors.initials: JL
authors.lastname: Kuti
authors.affiliation: Riley Hospital for Children, Indianapolis, IN, USA.
authors.forename: Rebecca S
authors.initials: RS
authors.lastname: Pettit
authors.affiliation: Columbia University, New York, NY, USA.
authors.forename: Natalie
authors.initials: N
authors.lastname: Neu
authors.affiliation: St Christopher's Hospital for Children, Philadelphia, PA, USA.
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Cies
authors.affiliation: CT Children's Medical Center, Hartford, CT, USA.
authors.forename: Craig
authors.initials: C
authors.lastname: Lapin
authors.affiliation: University of North Carolina, Chapel Hill, NC, USA.
authors.forename: Marianne S
authors.initials: MS
authors.lastname: Muhlebach
authors.affiliation: Nationwide Children's Hospital, Columbus, OH, USA.
authors.forename: Kimberly J
authors.initials: KJ
authors.lastname: Novak
authors.affiliation: Children's Medical Center, Dallas, TX, USA.
authors.forename: Sean T
authors.initials: ST
authors.lastname: Nguyen
authors.affiliation: Columbia University, New York, NY, USA.
authors.forename: Lisa
authors.initials: L
authors.lastname: Saiman
authors.affiliation: Center for Anti-Infective Research & Development, Hartford Hospital, Hartford, CT, USA.
authors.forename: David P
authors.initials: DP
authors.lastname: Nicolau
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications*; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D047090:beta-Lactams / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D047090:beta-Lactams
keywords: Antibiotic; Beta-lactam; Cystic fibrosis; Pseudomonas; Susceptibility